LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Sana Biotechnology Inc

Slēgts

SektorsVeselības aprūpe

2.82 -1.05

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

2.79

Max

2.9

Galvenie mērījumi

By Trading Economics

Ienākumi

-320K

-49M

EPS

-0.2

Darbinieki

194

EBITDA

-1.8M

-47M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+218.97% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 6. aug.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

163M

589M

Iepriekšējā atvēršanas cena

3.87

Iepriekšējā slēgšanas cena

2.82

Ziņu noskaņojums

By Acuity

50%

50%

154 / 380 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

Sana Biotechnology Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 27. jūn. 20:51 UTC

Peļņas

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

2025. g. 27. jūn. 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 27. jūn. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 27. jūn. 20:48 UTC

Tirgus saruna

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

2025. g. 27. jūn. 20:46 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 27. jūn. 20:46 UTC

Tirgus saruna

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

2025. g. 27. jūn. 19:31 UTC

Tirgus saruna

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

2025. g. 27. jūn. 19:19 UTC

Tirgus saruna

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

2025. g. 27. jūn. 19:16 UTC

Tirgus saruna

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

2025. g. 27. jūn. 18:57 UTC

Iegādes, apvienošanās, pārņemšana

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

2025. g. 27. jūn. 18:57 UTC

Iegādes, apvienošanās, pārņemšana

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

2025. g. 27. jūn. 18:57 UTC

Iegādes, apvienošanās, pārņemšana

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

2025. g. 27. jūn. 18:57 UTC

Iegādes, apvienošanās, pārņemšana

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

2025. g. 27. jūn. 18:57 UTC

Iegādes, apvienošanās, pārņemšana

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

2025. g. 27. jūn. 18:42 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 27. jūn. 18:42 UTC

Tirgus saruna

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

2025. g. 27. jūn. 18:39 UTC

Tirgus saruna
Peļņas

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

2025. g. 27. jūn. 18:29 UTC

Tirgus saruna

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

2025. g. 27. jūn. 18:18 UTC

Tirgus saruna

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

2025. g. 27. jūn. 18:16 UTC

Tirgus saruna

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

2025. g. 27. jūn. 17:16 UTC

Tirgus saruna

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

2025. g. 27. jūn. 17:08 UTC

Peļņas

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

2025. g. 27. jūn. 16:52 UTC

Iegādes, apvienošanās, pārņemšana

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

2025. g. 27. jūn. 16:22 UTC

Peļņas

These Stocks Are Moving the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

2025. g. 27. jūn. 16:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 27. jūn. 16:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 27. jūn. 16:20 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2025. g. 27. jūn. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 27. jūn. 15:59 UTC

Tirgus saruna

Gold Futures Slump on Improving Risk Appetite -- Market Talk

2025. g. 27. jūn. 15:56 UTC

Tirgus saruna

Nvidia Again Helping To Power New S&P Highs -- Market Talk

Salīdzinājums

Cenas izmaiņa

Sana Biotechnology Inc Prognoze

Cenas mērķis

By TipRanks

218.97% augšup

Prognoze 12 mēnešiem

Vidējais 9.25 USD  218.97%

Augstākais 15 USD

Zemākais 5 USD

Pamatojoties uz 5 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Sana Biotechnology Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

5 ratings

5

Pirkt

0

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

1.68 / 1.87Atbalsts un pretestība

Īstermiņā

Strong Bullish Evidence

Vidējā termiņā

Weak Bearish Evidence

Ilgtermiņā

No Evidence

Noskaņojums

By Acuity

154 / 380 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.